Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 12-15, 2025 in Honolulu, Hawaii. Both presentations report real world outcomes from patients with hematopoietic stem cell transplant-associated t.
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
On Thursday, Omeros Corporation OMER announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab.
Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). Th.
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros' investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held December 7-10, 2024 in San Diego. The zaltenibart abstracts are directed to the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening hem.
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company's first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”). In last week's quarterly earnings release and associated call, Omeros stated that it was awaiting feedback.
Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor and Media relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President, Clinical Development Conference Call Participants Steve Brozak - WBB Olivia Brayer - Cantor Fitzgerald Serge Belanger - Needham & Company Operator Good afternoon, and welcome to today's conference call for Omeros Corporation. At this time, all participants are in a listen-only mode.
Omeros Corporation Reports Third Quarter 2024 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. For the nine months ended September 30, 2024, net loss was $125.5 million, or $2.15 per share, compared to a net loss of $108.8.
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the.
Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor Relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President-Clinical Development Conference Call Participants Steve Brozak - WBB Securities Olivia Brayer - Cantor Fitzgerald John Gionco - Needham & Company Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conferen.
Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 6, 2024, starting at 10:00 a.m. Pacific Time. A live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2024. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting. A.
Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has completed a series of strategic financial transactions, further strengthening its balance sheet and extending the maturity profile on a substantial portion of its debt from February 2026 to June 2028, while providing a secure source of capital to support potential commercialization of its lectin pathway inhibitor narsoplimab and flexibility to manage the remaining balance of 2026 convertible notes. Today, Om.
